Insulinomas are rare but the commonest among pancreatic neuroendocrine tumours (pNET).1 Most are intrapancreatic, benign and solitary and have an excellent prognosis after surgical removal. The majority are <2 cm in size and distributed equally in the head, body and tail of the pancreas.2 Thus, preoperative localization is key to planning surgery. This will prevent prolonged intraoperative attempts to locate and at worst failure to remove the lesion despite laparotomy. Techniques used in preoperative localization include transabdominal ultrasonography, contrast enhanced computed tomography (CECT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS) and selective arterial calcium stimulation with hepatic venous sampling.2 We present a patient with endogenous hyperinsulinaemic hypoglycaemia in whom successful localization was achieved with selective arterial calcium stimulation (SACS) with hepatic venous sampling and intra-operative ultrasonography (IOUS) after cross sectional imaging failed to localize the lesion. To our knowledge, this is the first such report from Sri Lanka and highlights the benefits of harnessing multidisciplinary expertise to achieve optimal outcomes in challenging cases.

A 39-year-old male was evaluated for clinical features of hypoglycaemia of 10 months. These episodes corresponded with low capillary blood glucose (CBG) assays of up to 46 mg/dl and fulfilled Whipple’s triad. He had an otherwise normal premorbid status and clinical examination was unremarkable. A supervised 72-hour fast combined with CBG (31mg/dl) serum insulin (71.28 pmol/L [normal <21 pmol/L]) and C-peptide level (2.57 nmol/L [normal <0.2 nmol/L]) and negative sulfonylurea test confirmed endogenous insulin dependent hypoglycaemia. Multiple endocrine neoplasia I (MEN I) syndrome screening was negative.

Contrast enhanced CT abdomen in the early arterial phase and MRI with gadolinium contrast failed to demonstrate a pancreatic lesion (Fig. 1). SACS was performed as per standard protocol.3 In brief, selective cannulation and calcium injection into arteries supplying segments of the pancreas was performed. Insulin assays were performed on pre and post calcium infusion catheter samples obtained from the hepatic veins (Fig. 2). A two-fold rise in insulin levels above the baseline was observed in the proximal and distal splenic artery branches, localizing the tumour to the distal body or tail of the pancreas (Fig. 3, Table 1).

Surgery was performed through a bilateral subcostal incision. The pancreatic body and tail were mobilized with the spleen but the tumour could not be located by palpation. Intraoperative ultrasonography (IOUS) located a 1.0× 0.8 cm tumour in the pancreatic tail adjacent to the splenic hilum and this was enucleated (Fig. 4). IOUS also excluded the presence of multiple tumours (Fig. 5). Histology confirmed a WHO grade 1 tumour (Ki67 - 1.8%) pNET or insulinoma (positive staining for NSE). The patient made an uneventful recovery and was normoglycaemic at follow up more than a year later.

Most sporadic insulinomas are solitary and under 2 cm; hence parenchymal sparing complete enucleation is the procedure of choice to minimise morbidity while preventing recurrence. Tumour localization facilitates this and changes in surgical approach if necessary and is an integral part of workup. This case highlights the challenges of pre and intraoperative localization of insulinomas and tools to overcome them.

Cross sectional imaging failed to localise the tumour in this patient. This is not surprising considering that the sensitivity of contrast CT and MRI has been reported to range between 33-64% and 40-90%, respectively.4,5 This variability is likely dependent on tumour size, type of machine, protocols used and the expertise of radiologist.

EUS has proven to be a an effective modality in these situations with an overall sensitivity of 80-90% though this drops sharply for tumours in the tail (37-50%).6,7 The lack of available expertise at the time precluded its use in this patient.

SACS is an interventional radiological technique used to preoperatively localize or regionalize occult insulinomas with excellent sensitivity (84-100%) and specificity (94- 100%).8-11 Only 20% of patients who undergo surgical management for insulinoma require preoperative SACS, as the majority are localized with non-invasive imaging.12 SACS was developed by Doppman et al.8,13,14 in 1989 as a way to localize discrete insulin-secreting islet cell tumours of the pancreas. It is used on the basis that insulinomas have a dominant arterial supply and calcium elicits a unique response on tumour cells causing an insulin surge.14 A two-fold rise in the insulin levels above the baseline localizes the insulinoma to the anatomic region perfused by the injected artery. Fortunately, this study facilitated localization of the tumour to the distal body or tail in this patient.

Preoperative knowledge of the pancreatic segment containing the insulinoma facilitates directed visual examination and palpation to locate the tumour. Despite this, the tumour proved to be elusive and was only located nestled in the tail within the splenic hilum using IOUS. IOUS in combination with intraoperative palpation by an experienced operator has been shown to achieve excellent detection rates of 80-100%.15,16 Recurrence rates for sporadic insulinoma after surgery is 5% at 10 years and 7% at 20 years.17 Therefore our patients likelihood of recurrence is very low. The patient was well and normoglycaemic more than a year after surgery.

In conclusion, preoperative localization of insulinomas is mandatory to achieve good results with minimum morbidity. SACS is an invaluable adjunct when cross-sectional imaging fails to do this. IOUS, visualization and palpation during surgical exploration compliment preoperative localization. Timely referral to tertiary centres equipped with multidisciplinary expertise improves outcomes.